• Something wrong with this record ?

Survival improvements in esophageal and gastric cancers in the Nordic countries favor younger patients

K. Hemminki, F. Zitricky, A. Försti, O. Hemminki, V. Liska, A. Hemminki

. 2024 ; 13 (15) : e7365. [pub] -

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc24019447

Grant support
Novo Nordisk Fonden
Jane ja Aatos Erkon Säätiö
Finnish Cancer Organizations
856620 Horizon 2020 Framework Programme
Sigrid Juselius Foundation
Päivikki ja Sakari Sohlbergin Säätiö
University of Helsinki, Helsinki University Central Hospital
LX22NPO5102 National Institute for Cancer Research - NICR, Programme EXCELES,
The Cooperatio Program, research area SURG

Esophageal cancer (EC) and gastric cancer (GC) are fatal cancers with a relatively late age of onset. Age is a negative risk factor for survival in many cancers and our aim was to analyze age-specific survival in EC and GC using the recently updated NORDCAN database. NORDCAN data originate from the Danish, Finnish, Norwegian, and Swedish nationwide cancer registries covering years 1972 through 2021 inviting for comparison of 50-year survival trends between the countries. Relative 1- and 5-year survival and 5/1-year conditional survival (i.e., survival in those who were alive in Year 1 to survive additional 4 years) were analyzed. Survival in EC showed large gains for patients below age 80 years, 5-year survival in Norwegian men reaching 30% and in women over 30% but for 80-89 year old survival remained at 10%. In contrast, hardly any gain was seen among the 80-89 year patients for 1-year survival and small gains in 5 year and 5/1-year survival. Survival gaps between age-groups increased over time. For GC there was also a clear age-related negative survival gradient but the survival gaps between the age groups did not widen over time; Norwegian male and female 5-year survival for 80-89 year old was about 20%. The age-specific survival difference in GC arose in Year 1 and did not essentially increase in 5-year survival. While there were differences in survival improvements between the countries, poor survival of the 80-89 year old patients was shared by all of them. To conclude, survival has improved steadily in younger GC and EC patients in most Nordic countries. While the 80-89 year old population accounts for nearly a quarter of all patients and their poor survival depressed overall survival, which can therefore be increased further by improving diagnostics, treatment and care of elderly EC and GC patients.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24019447
003      
CZ-PrNML
005      
20241024110730.0
007      
ta
008      
241015s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/cam4.7365 $2 doi
035    __
$a (PubMed)39096090
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Hemminki, Kari $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic $u Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany $1 https://orcid.org/0000000227693316 $7 mzk20201092711
245    10
$a Survival improvements in esophageal and gastric cancers in the Nordic countries favor younger patients / $c K. Hemminki, F. Zitricky, A. Försti, O. Hemminki, V. Liska, A. Hemminki
520    9_
$a Esophageal cancer (EC) and gastric cancer (GC) are fatal cancers with a relatively late age of onset. Age is a negative risk factor for survival in many cancers and our aim was to analyze age-specific survival in EC and GC using the recently updated NORDCAN database. NORDCAN data originate from the Danish, Finnish, Norwegian, and Swedish nationwide cancer registries covering years 1972 through 2021 inviting for comparison of 50-year survival trends between the countries. Relative 1- and 5-year survival and 5/1-year conditional survival (i.e., survival in those who were alive in Year 1 to survive additional 4 years) were analyzed. Survival in EC showed large gains for patients below age 80 years, 5-year survival in Norwegian men reaching 30% and in women over 30% but for 80-89 year old survival remained at 10%. In contrast, hardly any gain was seen among the 80-89 year patients for 1-year survival and small gains in 5 year and 5/1-year survival. Survival gaps between age-groups increased over time. For GC there was also a clear age-related negative survival gradient but the survival gaps between the age groups did not widen over time; Norwegian male and female 5-year survival for 80-89 year old was about 20%. The age-specific survival difference in GC arose in Year 1 and did not essentially increase in 5-year survival. While there were differences in survival improvements between the countries, poor survival of the 80-89 year old patients was shared by all of them. To conclude, survival has improved steadily in younger GC and EC patients in most Nordic countries. While the 80-89 year old population accounts for nearly a quarter of all patients and their poor survival depressed overall survival, which can therefore be increased further by improving diagnostics, treatment and care of elderly EC and GC patients.
650    _2
$a lidé $7 D006801
650    12
$a nádory jícnu $x mortalita $x epidemiologie $7 D004938
650    12
$a nádory žaludku $x mortalita $x epidemiologie $7 D013274
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a senioři $7 D000368
650    _2
$a lidé středního věku $7 D008875
650    _2
$a věkové faktory $7 D000367
650    12
$a registrace $7 D012042
650    _2
$a dospělí $7 D000328
650    _2
$a míra přežití $7 D015996
651    _2
$a Skandinávie a severské státy $x epidemiologie $7 D012537
655    _2
$a časopisecké články $7 D016428
700    1_
$a Zitricky, Frantisek $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic $1 https://orcid.org/0000000176007143
700    1_
$a Försti, Asta $u Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany $u Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany
700    1_
$a Hemminki, Otto $u Department of Urology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland $u Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland
700    1_
$a Liska, Vaclav $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic $u Department of Surgery, University Hospital, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Hemminki, Akseli $u Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland $u Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland $1 https://orcid.org/0000000171038530
773    0_
$w MED00181704 $t Cancer medicine $x 2045-7634 $g Roč. 13, č. 15 (2024), s. e7365
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39096090 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024110724 $b ABA008
999    __
$a ok $b bmc $g 2201970 $s 1231420
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 13 $c 15 $d e7365 $e - $i 2045-7634 $m Cancer medicine $n Cancer Med $x MED00181704
GRA    __
$p Novo Nordisk Fonden
GRA    __
$p Jane ja Aatos Erkon Säätiö
GRA    __
$p Finnish Cancer Organizations
GRA    __
$a 856620 $p Horizon 2020 Framework Programme
GRA    __
$p Sigrid Juselius Foundation
GRA    __
$p Päivikki ja Sakari Sohlbergin Säätiö
GRA    __
$p University of Helsinki, Helsinki University Central Hospital
GRA    __
$a LX22NPO5102 $p National Institute for Cancer Research - NICR, Programme EXCELES,
GRA    __
$p The Cooperatio Program, research area SURG
LZP    __
$a Pubmed-20241015

Find record

Citation metrics

Archiving options